
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ZNF703 CRISPR/Cas9 KO Plasmid (h) | sc-406411 | 20 µg | $397.00 |
ZNF703 (zinc finger protein 703) is a nuclear transcriptional regulator implicated in controlling gene expression programs linked to epithelial differentiation, cell-cycle progression, and lineage specification. As a member of the NET/NLZ family, ZNF703 can function within transcriptional repression and chromatin-associated complexes to modulate developmental signaling and downstream transcriptional networks. Dysregulated ZNF703 expression has been associated with altered proliferative and migratory phenotypes and is frequently studied in the context of 8p12 amplicon biology in breast cancer research. These features make ZNF703 a useful target for investigating transcription factor–driven regulatory circuitry, oncogenic transcriptional states, and pathway dependencies in human cell models.
ZNF703 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ZNF703 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ZNF703 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ZNF703 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ZNF703 protein expression.
This CRISPR knockout system enables efficient generation of ZNF703-deficient cell models for investigation of ZNF703 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.